Skip to main content
. 2022 May 19;2022:3601942. doi: 10.1155/2022/3601942

Table 3.

Differences in overall survival associated with immunotherapy in age by subgroups.

Participants, no. Pooled HR (95% CI) for ICI vs. controlled therapies Test for difference
Variable Studies, no. <65 ≥65 <65 ≥65 P value
Overall 18 7092 5715 0.74 (0.68, 0.81) 0.80 (0.75, 0.86) 0.17
Line of therapy
 First 11 4286 3561 0.74 (0.65, 0.85) 0.80 (0.73, 0.87) 0.351
 Subsequent 7 2806 2154 0.73 (0.64, 0.83) 0.80 (0.69, 0.92) 0.367
Intervention therapy
 ICI alone 11 4268 3369 0.74 (0.66, 0.83) 0.78 (0.72, 0.85) 0.468
 ICI combined with non-ICI 7 2824 2346 0.73 (0.63, 0.86) 0.83 (0.74, 0.94) 0.203
Pathologic types
 Squamous 4 1112 973 0.69 (0.53, 0.91) 0.82 (0.65, 1.05) 0.358
 Nonsquamous 5 2203 1664 0.74 (0.62, 0.88) 0.77 (0.67, 0.87) 0.72

Abbreviations: HR = hazard ratio; ICI = immune checkpoint inhibitor.